LB Pharmaceuticals Inc Common Stock (LBRX)

About LBRX

LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD;…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

49

Website

lbpharma.us/

Fundamentals

1-day range

$46.37$49.25

Market cap

$1.23B

P/E (trailing)

—

P/E (forward)

-9.48

EPS (trailing)

$-1.72

Dividend yield

—

Beta

1.59

Avg. volume

327.8K

Forecasts

8 analyst ratings

LB Pharmaceuticals Inc Common Stock Competitors

Chosen by industry and closest market cap.

• LBRX

  LB Pharmaceuticals Inc Common Stock

  $47.8

  ▼ 0.20%
  Market cap $1.23BP/E —
  $13.36$50.16
• ARDX

  Ardelyx Inc. Common Stock

  $3.81

  ▼ 0.26%
  Market cap $1.23BP/E —
  $3.73$8.4
• ETON

  Eton Pharmaceuticals Inc. Common Stock

  $59.79

  ▼ 4.60%
  Market cap $1.24BP/E 150.92
  $14.27$66.37
• MNKD

  MannKind Corporation Common Stock

  $3.96

  ▼ 2.59%
  Market cap $1.21BP/E —
  $2.23$6.51
• SDGR

  Schrodinger Inc. Common Stock

  $19.7

  ▼ 3.48%
  Market cap $1.14BP/E —
  $10.95$23.02
• CRVS

  Corvus Pharmaceuticals Inc. Common Stock

  $14.15

  ▼ 3.87%
  Market cap $1.12BP/E —
  $5.28$26.95
• SVRA

  Savara Inc. Common Stock

  $5.27

  ▼ 4.10%
  Market cap $1.09BP/E —
  $3.19$7.01

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• HC Wainwright & Co. Maintains Buy on LB Pharmaceuticals, Raises Price Target to $60
  benzinga · 8/24/2026

Institutional Ownership

March 31, 2026

Total shares held

26.50M

Total value held

$652.03M

Institutional holders

73